Personalized treatment of serious infections: From COVID-19 to bacterial sepsis.
Humanity is experiencing a devastating pandemic from the new SARS-CoV-2 (COVID-19) coronavirus. The disease is having a catastrophic impact on the conditions of our lives and our society.
Since early spring 2020, all members of the Hellenic Sepsis Study Group are united in a huge effort to understand the mechanism of the disease and to successfully develop treatment strategies. The result is 15 publications so far in international scientific journals. The crowning achievement, however, are the SAVE and- SAVE MORE studies corresponding to phase II and III development projects. The successful results of these two studies shaped the dossier submitted to the European Medicines Agency for final evaluation of the indication of anakinra for patients hospitalised with COVID-19 pneumonia and at risk of deterioration into severe respiratory failure.